A Study to Evaluate the Immunogenicity of Quadrivalent LAIV (MEDI8662) in Adults 18 to 49 Years of Age

NCT00952705 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1800

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy or Stable Underlying Chronic Medical Condition

Interventions

BIOLOGICAL: Q/LAIV-BFS (MEDI8662)
BIOLOGICAL: FluMist/B/Yamagata
BIOLOGICAL: FluMist/B/Victoria

Sponsor

MedImmune LLC